Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus, Dana Ivancovsky Wajcman,Henry E. Mark,Zobair M. Younossi, Christopher J. Kopka, Nevin Cohen,Meena B. Bansal, Michael Betel, Paul N. Brennan

NATURE MEDICINE（2024）

引用 0|浏览8

暂无评分

摘要

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要